In pancreatic cancer cells for instance, EGFR inhibitor gefinitib in combination with cyclopamine, has shown a tumor growth decrease and apoptotic rate increase [32], whereas in prostate cancer cells, cyclopamine in combination with gefitinib and docetaxel treatment has demonstrated an inhibitory effect on proliferation and invasiveness [33]. This evidence concerns the gene EGFR and prostate cancer.